David H.  Deming net worth and biography

David Deming Biography and Net Worth

David H. Deming has served as a member of the Board since February 2025 and currently serves as our Lead Independent Director. Mr. Deming currently serves as the President and CEO of Barramundi Capital LLC (formerly Parker Street Securities), a broker-dealer for private placements of private securities, a position he has held since April 2023. Mr. Deming has also been a Senior Advisor at ID Fund Advisors LLC, a registered investment adviser, since June 2018. From April 2013 to February 2018, Mr. Deming served as Managing Partner of TAG Healthcare Advisors, where he advised healthcare companies on business and financial strategies. Mr. Deming currently serves on the board of directors of Better For You Wellness, Inc. (OTC: BFYW), where he is a member of the audit committee. Mr. Deming began his career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College.

What is David H. Deming's net worth?

The estimated net worth of David H. Deming is at least $43.10 thousand as of November 12th, 2026. Deming owns 58,800 shares of Phio Pharmaceuticals stock worth more than $43,100 as of November 16th. This net worth evaluation does not reflect any other investments that Deming may own. Learn More about David H. Deming's net worth.

How do I contact David H. Deming?

The corporate mailing address for Deming and other Phio Pharmaceuticals executives is 411 Swedeland Road, Suite 23-1080, King OF Prussia, PA, 19406. Phio Pharmaceuticals can also be reached via phone at (508) 767-3861 and via email at [email protected]. Learn More on David H. Deming's contact information.

Has David H. Deming been buying or selling shares of Phio Pharmaceuticals?

Within the last three months, David H. Deming has bought $19,860.00 in Phio Pharmaceuticals stock. Most recently, on Friday, November 13th, David H. Deming bought 3,000 shares of Phio Pharmaceuticals stock. The stock was acquired at an average cost of $0.83 per share, with a total value of $2,490.00. Following the completion of the transaction, the director now directly owns 61,800 shares of the company's stock, valued at $51,294. Learn More on David H. Deming's trading history.

Who are Phio Pharmaceuticals' active insiders?

Phio Pharmaceuticals' insider roster includes Robert Bitterman (President & Chief Executive Officer), Patricia Bradford (Director), David Deming (Director), Gerrit Dispersyn (CEO), and Ronald Plott (Director). Learn More on Phio Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Phio Pharmaceuticals?

During the last year, Phio Pharmaceuticals insiders bought shares 14 times. They purchased a total of 120,800 shares worth more than $113,474.00. The most recent insider tranaction occured on November, 13th when Director David H Deming bought 3,000 shares worth more than $2,490.00. Insiders at Phio Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Phio Pharmaceuticals.

Information on this page was last updated on 11/13/2026.

David H. Deming Insider Trading History at Phio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2026Buy3,000$0.83$2,490.0061,800View SEC Filing Icon  
11/12/2026Buy9,000$0.81$7,290.0058,800View SEC Filing Icon  
11/11/2026Buy5,200$0.84$4,368.0049,800View SEC Filing Icon  
11/10/2026Buy6,800$0.84$5,712.0044,600View SEC Filing Icon  
See Full Table

David H. Deming Buying and Selling Activity at Phio Pharmaceuticals

This chart shows David H. Deming's buying and selling at Phio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phio Pharmaceuticals Company Overview

Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Read More

Today's Range

Now: $0.76
Low: $0.72
High: $0.77

50 Day Range

MA: $0.94
Low: $0.77
High: $1.08

2 Week Range

Now: $0.76
Low: $0.72
High: $1.88

Volume

75,458 shs

Average Volume

1,293,001 shs

Market Capitalization

$9.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93